Meanwhile, understanding of the cellular immune mechanisms paved the way for using the T cell growth factor interleukin-2 (IL-2) to stimulate anti-cancer CD8+ cytotoxic T lymphocytes (CTLs) in cancer patients and to expand these CTLs in vitro for the purpose of adoptive cell therapy (ACT) [10,11]. Here, IL2 is linked to cancer.